Question explored with the scientific record
Which Covid vaccine is most effective given current variants show specific vaccines and rank effectiveness
The short version: no evidence here ranks current vaccines against current variants. The data is too old, too narrow, or too conflicted to give a clear winner.
The evidence you gave me is a pile of studies from 2021–2024, most testing the original mRNA vaccines (BNT162b2, mRNA-1273) against early Omicron subvariants like BA.1 and BA.2 [7]. One study covers the BA.4/5 bivalent [6], and one tests an XBB.1.5 booster in a tiny group of transplant survivors [9]. None of these compare the vaccines head-to-head against the variants circulating today. The Egyptian cohort study [3] tested six different brands but had so few infections that all its effectiveness estimates came with confidence intervals crossing zero—meaning no statistically significant protection from vaccination alone was found. The systematic review [1] reports a wide range of effectiveness (8% to 71% against infection) and explicitly says heterogeneity prevented a meta-analysis.
The only comparative numbers come from a narrative review [5] that reports original-trial efficacy (95% for BNT162b2, 94.1% for mRNA-1273, 83.5% for CoronaVac) but those are against the ancestral virus, not current variants. Real-world effectiveness against Omicron BA.1/BA.2 dropped to 10% or below three months after the second dose [7]. The booster restored it to about 60% for a month, then it fell again [7]. The bivalent BA.4/5 study [6] found a 40% lower risk of long COVID symptoms, but that is a single observational study with 505 people, funded by Pfizer (the manufacturer), and the unvaccinated comparison group had last received a monovalent dose an average of 546 days prior—so the comparison is really "recent bivalent" vs "old monovalent," not vaccinated vs unvaccinated.
| Vaccine | Original efficacy (ancestral virus) | Effectiveness vs Omicron BA.1/BA.2 (2+ months post-booster) | Source |
|---|---|---|---|
| BNT162b2 (Pfizer) | 95% [5] | ~10% or below [7] | [5, 7] |
| mRNA-1273 (Moderna) | 94.1% [5] | Similar pattern to BNT162b2 [7] | [5, 7] |
| CoronaVac (Sinovac) | 83.5% [5] | Not tested in this evidence | [5] |
My call: There is no evidence here to rank current vaccines against current variants. The data is stale, the comparisons are missing, and the one study that tried to compare multiple brands found no significant protection from vaccination alone. Confidence: not clear—the question cannot be answered from the evidence retrieved.
Sources examined 11
-
P-2054. Effectiveness of a Single COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with SARS-CoV-2: A Systematic Review
A systematic review of 18 studies evaluating the effectiveness of a single mRNA COVID-19 vaccine dose in individuals with prior SARS-CoV-2 infection found substantial protection against infection, symptomatic disease, and hospitalization—comparable to two-dose regimens in immuno…
DOI: 10.1093/ofid/ofae631.2210 -
Comparisons Of Mrna Vaccine from Different Manufactures
A comparative review of three mRNA COVID-19 vaccines (Pfizer-BioNTech BNT162b2, Moderna mRNA-1273, and Walvax/ARCoV) covering target proteins, efficacy against infection and severe disease, safety, and cost, with recommendations tailored to cohorts and affordability.
DOI: 10.54097/hset.v45i.7392 -
Assessing SARS-CoV-2 vaccine effectiveness in health workers: a cohort study conducted during the pandemic decline phase in five hospitals, affiliated to Al-Azhar University- Egypt
A WHO-supported, multicenter prospective cohort study at five Al-Azhar University hospitals in Egypt evaluated SARS-CoV-2 vaccine effectiveness against symptomatic RT-PCR-confirmed infection among healthcare workers over about one year, finding no significant protection overall …
DOI: 10.1186/s12879-025-11446-9 -
Characteristics and Vaccine Booster Effectiveness in Covid-19 Infections Using 15 Days Post-Booster Period as Baseline during the Omicron Wave in A General Medicine office in Toledo (Spain)
In a small prospective general-practice study in Toledo, Spain during the Omicron wave (Dec 2021-Feb 2022), COVID-19 booster recipients who were infected <15 days after booster had a 60% lower relative risk of symptomatic infection than those infected ≥15 days post-booster, thou…
DOI: 10.31579/2639-4162/050 -
Mecanismo y diseño de vacunas para el sars-cov-2, revisión narrativa
This narrative review describes SARS-CoV-2 vaccine mechanisms and designs, reporting that mRNA vaccines (BNT162b2 and mRNA-1273) demonstrate the highest efficacy (93-95%), adenovirus vector vaccines show 66.9-91.6% efficacy, and inactivated CoronaVac shows 83.5%, with rare safet…
DOI: 10.18566/medupb.v43n1.a10 -
Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study
A nationwide US prospective study found that receipt of the BNT162b2 BA.4/5 bivalent COVID-19 vaccine was associated with about a 40% lower risk and reduced burden of long COVID symptoms over six months among symptomatic adults with SARS-CoV-2 infection, compared with those not …
DOI: 10.3390/vaccines12020183 -
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
This study estimates the duration of protection provided by mRNA COVID-19 vaccines against SARS-CoV-2 Omicron BA.1 and BA.2 infections in Qatar, revealing that effectiveness declines significantly over time but remains strong against hospitalization and death.
DOI: 10.1038/s41467-022-30895-3 -
Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients
Vaccination with BNT162b2 is associated with reduced COVID-19–related declines in health-related quality of life and work productivity and with faster recovery among mildly symptomatic US outpatient adults during Omicron circulation.
DOI: 10.1186/s41687-022-00528-w -
Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation
Comirnaty Omicron XBB.1.5 booster induces robust humoral and S1-specific T-cell responses in long-term allo-HSCT survivors, with immunosuppression dampening responses and prior SARS-CoV-2 infection shaping baseline immunity.
DOI: 10.1038/s41598-024-74712-x -
Acute vestibular neuritis: A rare complication after the adenoviral vector-based COVID-19 vaccine
This study presents a rare case of acute vestibular neuritis in a healthy 51-year-old male pilot following the ChAdOx1 nCoV-19 COVID-19 vaccination, highlighting the potential neurological complications associated with the vaccine.
DOI: 10.1007/s13365-022-01087-y -
Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
This study reports two cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) presenting with mild thrombocytopenia and venous thromboembolism following ChAdOx1 nCoV-19 vaccination, highlighting the spectrum of VITT severity and the importance of recognizing delayed …
DOI: 10.1055/a-1585-6182